Schrödinger, Inc. today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies.

Art in public places is said to inspire pride and interest in one’s community, and the installations themselves often become ...

Do you need some extra cash? Here are 50 side hustles for making money on the side. From freelancing to selling products, ...

The consequences of an abbreviated or disregarded discovery can result in generic, forgettable brand messaging or messaging ...

Apple's new haptic trailer for F1 The Movie syncs force feedback with on-screen action, available now on iPhones via the ...

A countdown clock has been unveiled at DFW Airport one year out from the 2026 FIFA World Cup. NBC 5’s Alanna Quillen tells us ...

The poster, Updated Results from the Ongoing Phase 1/2a Study of MP0533, a Tetra-Specific Designed Ankyrin Repeat Protein (DARPin; CD33 x CD123 x CD70 x CD3), in Patients with Relapsed/Refractory AML ...

The UAE has announced new media licensing fees. This is under Cabinet Decision No. (41) of 2025. The decision covers ...